(Deutsche Welle) A new study by scientists in Britain and Latvia has shown that the European Medicines Agency (EMA) approved 39 new cancer drugs between 2009 and 2013 without evidence that they worked.
A total of 68 cancer drugs were given a nod by the European drug regulator during the period.
“We were quite surprised about the high proportion of drugs entering the market without evidence,” said Huseyin Naci, of the London School of Economics and Political Science, one of the study’s authors.
The researchers found that only about half of the approved drugs significantly improved patient survival or their quality of life. The efficacies of the remaining drugs were “uncertain.”